# OnCo record paper-chawla-sq3370-phase-1-2a-advanced-solid-tumours-medrxiv-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-chawla-sq3370-phase-1-2a-advanced-solid-tumours-medrxiv-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-chawla-sq3370-phase-1-2a-advanced-solid-tumours-medrxiv-2025" ;
  schema:name "SQ3370 phase 1/2a results in advanced solid tumours and soft tissue sarcoma (preprint)"@en ;
  schema:alternateName "A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumors"@en ;
  schema:description "The full clinical results of the only trial of SQ3370, posted before peer review. The treatment was well tolerated at very high doses, but 2 of 14 sarcoma patients responded, about what ordinary doxorubicin achieves, and the trial was stopped."@en ;
  schema:url <https://onco.cc/key-papers/paper-chawla-sq3370-phase-1-2a-advanced-solid-tumours-medrxiv-2025/> ;
  schema:dateModified "2026-11-16"^^xsd:date ;
  schema:citation <https://doi.org/10.1101/2025.06.02.25328445>, <https://europepmc.org/article/PPR/PPR1030310>, <https://clinicaltrials.gov/study/NCT04106492> ;
  schema:sameAs <https://doi.org/10.1101/2025.06.02.25328445> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Chawla SP, Abella E, Wieland S, et al." ;
  onco:cancers <https://onco.cc/cancers/sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/click-activated-prodrugs/> ;
  onco:drugs <https://onco.cc/drugs/sq3370/> ;
  onco:companies <https://onco.cc/companies/shasqi/> ;
  onco:trials <https://onco.cc/trials/nct04106492/> ;
  onco:people <https://onco.cc/people/sant-chawla/> ;
  onco:journals <https://onco.cc/journals/medrxiv/> .
